Conclusions
The results of these exploratory analyses suggest that early treatment with a combination product containing both an NSAID and a triptan (i.e., sumatriptan-naproxen) may provide relief from symptoms of migraine and dysmenorrhea, as well as some of the neuropsychological symptoms related to these disorders. A triptan formulated with an NSAID may be advantageous in migraneurs with dysmenorrhea because many of these menstrual symptoms are thought to arise as the result of uterine prostaglandin release. Furthermore, the data suggest a relationship between the number of baseline moderate to severe menstrual symptoms and modulation of the primary outcome (migraine headache pain); the relative efficacy of sumatriptan-naproxen compared with placebo tended to decrease with the number of dysmenorrhea symptoms at baseline in this study.